Do you have the fat gene? This test could soon tell you
Scientists now think people who struggle with their weight may have drawn the genetic short-straw – and soon people will be able to find out if their genes are to blame for the struggle.
Work has begun in the UK on developing new tests that will spot if someone has 'fat genes'. The project, which seeks to create simple blood or saliva tests, is being undertaken by a team at Oxford gene start-up Genomics and Novo Nordisk, the Danish drug giant behind blockbuster weight-loss drug Wegovy and Ozempic.
The tests are expected to work by identifying if someone has the differences in their DNA that make them more prone to obesity.
Sir Peter Donnelly, chief executive of Genomics, said genetics is 'four times more important than lifestyle factors' when it comes to mapping if someone will become obese.
Studies have suggested that somebody with unhelpful genetics is around 10 times more likely to be obese in middle age than someone with helpful genes.
It can mean those people with these obesity genes have to work much harder to keep on top of their weight.
Research in the US has found that someone with 'unhelpful genetics' would have to walk 10,000 more steps than someone with 'helpful genetics' to maintain a healthy weight.
Sir Peter said: 'There's not a single gene which matters for obesity or for heart disease or other diseases. There are more than a million places in our DNA, each of which has a tiny impact on our propensity for obesity.'
Scientists from Genomics will create an algorithm that can accurately map which DNA differences are most important in determining someone's likelihood of becoming obese. The team says they expect to launch tests within the next few years.
Sir Peter said change was needed over how people view obesity, adding: 'We have to start thinking about obesity as a condition, rather than some consequence of poor willpower.'
It comes as governments step up attempts to tackle the obesity crisis amid concerns that more people are becoming severely overweight. Figures released last month revealed that more than three in four adults in the UK will be obese or overweight by 2050.
Nadeem Sarwar, who heads up Novo Nordisk's 'transformational prevention unit', said the UK could be a pioneer in tackling obesity by stopping it before the disease progresses.
Novo Nordisk recently set up the 'transformational prevention unit' (TPU), which is anchored in the UK, to 'predict, pre-empt and prevent' obesity.
Alongside the tests for obesity, Novo Nordisk is also seeking to develop treatments that can then be targetted to those who test positive for fat genes.
Mr Sarwar said: 'Just telling someone, 'You're high risk for disease, good luck' is not really going to help them that much. So at the TPU, we're putting in as much effort on developing products that will help prevent the risk as much as we are to pre-empt the risk.'
Wes Streeing, the Health Secretary, has said he wants to shift the NHS's focus from 'sickness to prevention'. Already, the Government has clamped down on junk food ads in an attempt to curb obesity levels, saying the disease costs the NHS billions of pounds every year.
Mr Sarwar said: 'The UK, I think rightly, is emphasising the importance of prevention.'
Novo Nordisk is developing more preventative treatments for obesity as competition heats up in the weight-loss market.
Up until this point, Novo Nordisk has been outselling US rival Eli Lilly for its weight-loss treatments, which help people lose an average of 15pc of their body mass by suppressing appetite.
However, the two companies have been battling to break new ground on weight-loss treatments. Earlier this month, Novo Nordisk's shares dropped as much as 7pc after Eli Lilly released trial data suggesting it had created a weight-loss pill that worked just as well as Wegovy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
an hour ago
- Telegraph
Third of young people want fat jabs as demand spirals
A third of young adults want to take fat jabs amid a surge in demand for the drugs, pharmacists have said. One in five people say they have tried to access a pharmacy weight-loss treatment in the past year but this figure is 35 per cent for those aged between 16 and 34. Pharmacists have raised the alarm that demand has far exceeded what can be clinically delivered. Concerns have also been raised that people could resort to looking for drugs such as Wegovy and Mounjaro from online sellers. Current guidelines state that patients being prescribed Mounjaro and Wegovy through pharmacies need a BMI of at least 35 and at least one weight-related comorbidity, such as diabetes, to be eligible. Wegovy can also be prescribed to patients with a BMI of 30–34 who meet the criteria for referral to specialist overweight and obesity management services. However, the NHS is only rolling out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities. It spent £269million on fat jabs in 2024-2025 and prescriptions doubled to almost three million a year. Mounjaro, regarded as the strongest jab and known as King Kong, has driven the spike in prescriptions with 1.1million given out in a year compared with 3,300 in the previous 12 months. The National Pharmacy Association (NPA), which represents about 6,000 pharmacies, surveyed 2,000 Britons and found evidence of demand beyond what the NHS can offer. It is now seeking greater clarity on how pharmacies will be further involved in the distribution of weight-loss medication, something laid out in the Government's recent 10 Year Health Plan. Olivier Picard, chairman of the NPA, said: 'Weight-loss jabs are one of the biggest drug innovations this century but growing demand highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight-loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from medication. 'We're also urging the Government to bring forward plans to include pharmacies in the rollout of their NHS weight-management programme. 'Pharmacists are experts in medication and many have extensive experience delivering weight-loss injections as part of a package of care including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS and help people make the best use of these powerful medicines,' he added
Metro
2 hours ago
- Metro
GP reveals 5 common mistakes people make when stopping weight loss jabs
While treatments like Ozempic, Mounjaro and Wegovy can provide a helping hand, there's no magic bullet when it comes to losing weight. Given GLP-1 agonist medications have been shown to help people lose up to four times more than going it alone, it's no wonder they're popular. However, a proportion of the estimated 1.5 million people in the UK who are now on these jabs will struggle to keep the pounds off long-term — and some may even end up heavier than when they started. 'While it can differ depending on the individual, it's quite common for people to regain some of the weight lost once they stop taking the medication,' Dr Donald Grant, GP and senior clinical advisor at The Independent Pharmacy, tells Metro. There are a few factors behind this, from metabolism to appetite. But going back on your progress isn't inevitable, as long as you're careful to avoid these five common pitfalls. As these treatments work by suppressing appetite, Dr Grant warns that going cold turkey 'could increase it, leading to poor eating habits and potential weight gain.' If you're considering coming off your medication, he recommends speaking to your GP about doing so slowly and safely. 'A medical professional can advise further on a potential tapering plan, while also providing dietary advice and lifestyle habits that can help reduce weight gain,' he adds. According to a recent study of over 6,000 people by scientists at Oxford University, those who use GLP-1 drugs will put their weight back on within 10 months of stopping if they don't continue to maintain a healthy lifestyle. Dr Grant explains: 'When stopping weight loss injections, it's crucially important that individuals replace the treatment with another way to keep weight off.' Even 30 minutes of daily exercise can make all the difference, burning off some of those extra calories you're consuming and stopping you falling into a sedentary routine. Quick fixes and 'crash diets' rarely result in any lasting improvements — and the same is true for GLP-1 medications. 'Choosing to stop weight loss treatment too early is by far one of the most common errors people make,' says Dr Grant. 'These drugs are designed to be used long-term, but not doing so gives the body little time to adapt to the treatment.' It's a marathon, not a sprint, with many providers recommending a course of between 12 and 24 months. Unless you're prepared to make that commitment, you may not reap the full benefits of treatment. Making changes to your diet while taking Ozempic, Mounjaro or Wegovy is a vital step to maintaining your progress forward. In fact, Dr Grant claims failure to do so is a 'sure-fire way to regain weight lost'. 'It's important for people to draw up a dietary plan, including structured meal times to avoid overeating,' he explains. More Trending 'I also recommend a well-balanced diet including a variety of high-protein, fibre-rich and healthy fat foods.' 'While it's important not to create an unhealthy relationship with weight management, tracking weight closely once ending any treatments can help people adjust their routine to avoid losing progress,' says Dr Grant. It's easy to revert to old habits once you end a course of medication, but regular monitoring ensures you can get back on track before you lose too much progress. View More » Since you've put so much time, energy and potentially money into the progress you've made so far, just think of this as protecting your investment. Do you have a story to share? Get in touch by emailing MetroLifestyleTeam@ MORE: 'I've tried jabs and pills to lose weight – but my latest attempt is the most extreme' MORE: Lives at risk because we've already forgotten a basic mantra MORE: The golden rule for how long it should take you to pee Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
The Guardian
6 hours ago
- The Guardian
Demand for weight loss drugs is becoming unsustainable, say pharmacists
Demand for weight loss drugs is becoming so 'unsustainable' that demand may soon outstrip supply, pharmacists have warned. The National Pharmacy Association (NPA) said supply problems could encourage people to turn to unregulated online sources, despite the risks involved. The number of people in the UK using drugs such as Wegovy and Mounjaro has soared to well above a million, with most patients paying to get them privately. During April, 1.6m packs of Mounjaro and Wegovy were bought in Britain, with the number thought to correlate closely with the number of people using them. 'Spiralling demand for weight loss medication risks going far beyond what is clinically deliverable', the NPA said. The drugs might need to be reserved for those in greatest need because they are so overweight instead of being given to the 'worried well', it added. New polling has found that 21% of Britons have tried to get hold of the medications over the past year, a figure that rises to 35% among 18- to 34-year-olds. The same survey found that 41% of all age groups would use them if they were free on the NHS. This figure rose to 64% among those aged 25-34. Savanta interviewed a representative sample of 2,002 adults aged 18 or over online from 20-23 June for the NPA, which represents 6,000 independent pharmacies. 'Weight loss jabs are one of the biggest drug innovations this century but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it,' said Olivier Picard, the NPA's chair. 'It's clear from this polling that more people are interested in getting weight loss jabs than can benefit from weight loss medication.' Supply of the medicines has been hit by shortages in some parts of the UK, including for higher doses of Mounjaro, the NPA said. Supply has been restricted to some pharmacies, which has stopped some new patients from going on to the drugs. The Medicines and Healthcare products Regulatory Agency, the UK's drugs watchdog, has warned patients to obtain the drugs only with a doctor's prescription, and not from beauty parlours or websites. A Department of Health spokesperson said more people would be able to obtain 'revolutionary' weight loss jabs over the next few years. 'Weight loss drugs are a powerful tool in tackling the obesity crisis head-on as part of our 10-year health plan', they added. 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to do so in a safe and controlled way. We will ensure that those most in need will receive treatment first.' About 220,000 people in England are due to be offered tirzepatide, a diabetes drug that promotes weight loss, over the next three years. Pharmacies already provide about 85% of all weight loss drugs and need to be closely involved in the expansion of access, Picard added. 'The government should use the massive untapped expertise and skills of pharmacists to help speed up the NHS's weight loss medication programme to millions of the most in need patients,' he said.
